Verification evidence is still being completed.
PDF / print export
Faron Pharmaceuticals
Turku, Finland
- Verified lead
- Juho Jalkanen
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Precision Immunotherapy and Clinical-Stage Macrophage Reprogramming
- Review cycle
- May 2026
- Full address
- Joukahaisenkatu 6, FI-20520 Turku, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Faron management team page confirming Juho Jalkanen as Chief Executive Officer.
- Editorial note
- Faron extends the Finnish layer with a current executive disclosure, a live 2025 annual-report surface, and a clearly attributable Turku headquarters record.
Precision Immunotherapy and Clinical-Stage Macrophage Reprogramming
Clinical-stage immunotherapy operations, Public-company governance and reporting
Faron extends the Finnish layer with a current executive disclosure, a live 2025 annual-report surface, and a clearly attributable Turku headquarters record.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Turku, Finland
Faron Pharmaceuticals
Precision Immunotherapy and Clinical-Stage Macrophage Reprogramming · Clinical-stage therapeutic development
Verified 15 Mar 2026 · 3 sources
Clinical
Faron extends the Finnish layer with a current executive disclosure, a live 2025 annual-report surface, and a clearly attributable Turku headquarters record.
Contact & location
- Website
- faron.com
- Company page
- Lead
- Juho Jalkanen (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 15 Mar 2026 (3mo ago)
- Scale
- Clinical-stage therapeutic development
- Capabilities
- Precision Immunotherapy · Bexmarilimab Development · Clinical Biomarker Strategy
- Founded
- 2003
- Headcount
- 11-50
Clinical profileSTATUS: VERIFIED MARCH 2026
Juho Jalkanen
Chief Executive Officer
Full addressJoukahaisenkatu 6, FI-20520 Turku, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage therapeutic development
Turku, Finland. Precision Immunotherapy and Clinical-Stage Macrophage Reprogramming. Review completed on 15 Mar 2026.
Fimea, EMA, and clinical-trial oversight
Clinical-stage immunotherapy operations, Public-company governance and reporting
Precision Immunotherapy and Clinical-Stage Macrophage Reprogramming
Faron extends the Finnish layer with a current executive disclosure, a live 2025 annual-report surface, and a clearly attributable Turku headquarters record.
Editorial note
Faron extends the Finnish layer with a current executive disclosure, a live 2025 annual-report surface, and a clearly attributable Turku headquarters record.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Precision Immunotherapy
Bexmarilimab Development
Clinical Biomarker Strategy
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Immunology development laboratories
Biomarker analytics
Clinical operations systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
15 Mar 2026: Executive identity confirmed via official management disclosure.
15 Mar 2026: Trust review remains in progress.
FAQ
Frequently asked questions
- Where is Faron Pharmaceuticals located?
- Faron Pharmaceuticals operates from Joukahaisenkatu 6, FI-20520 Turku, Finland, Turku, Finland.
- Who runs Faron Pharmaceuticals?
- Faron Pharmaceuticals is led by Juho Jalkanen, Chief Executive Officer. Verified 15 Mar 2026.
- What does Faron Pharmaceuticals do?
- Faron extends the Finnish layer with a current executive disclosure, a live 2025 annual-report surface, and a clearly attributable Turku headquarters record. Core capabilities: Precision Immunotherapy, Bexmarilimab Development, Clinical Biomarker Strategy.
Editorial context
Related technical briefs
Briefs that name Turku as a covered market or city.